tiprankstipranks
Advertisement
Advertisement

SE:CANTA Stock Latest News

Cantargia Reiterated as Buy on Nadunolimab’s Strong Early Data and Pipeline Progress; Price Target Maintained at SEK14
RatingsCantargia Reiterated as Buy on Nadunolimab’s Strong Early Data and Pipeline Progress; Price Target Maintained at SEK14
4d ago
Cantargia Reports Promising Early Remissions with Nadunolimab in High-Risk MDS and AML Trial
PremiumCompany Announcements
Cantargia Reports Promising Early Remissions with Nadunolimab in High-Risk MDS and AML Trial
4d ago
Cantargia Showcases New Nadunolimab Trial in Hard-to-Treat Colorectal Cancer at AACR 2026
PremiumCompany Announcements
Cantargia Showcases New Nadunolimab Trial in Hard-to-Treat Colorectal Cancer at AACR 2026
14d ago
Cantargia convenes 2026 AGM with focus on continuity in board
PremiumCompany Announcements
Cantargia convenes 2026 AGM with focus on continuity in board
14d ago
Cantargia Showcases Promising Nadunolimab Data in Hard-to-Treat Colorectal Cancer
PremiumCompany Announcements
Cantargia Showcases Promising Nadunolimab Data in Hard-to-Treat Colorectal Cancer
1M ago
Cantargia to Court Investors at Van Lanschot Kempen Life Sciences Conference
PremiumCompany AnnouncementsCantargia to Court Investors at Van Lanschot Kempen Life Sciences Conference
2M ago
Cantargia to Highlight Antibody Platform at TD Cowen Healthcare Conference
Premium
Company Announcements
Cantargia to Highlight Antibody Platform at TD Cowen Healthcare Conference
2M ago
Cantargia: Solid Cash Runway and Expanding Nadunolimab Pipeline Support Buy Rating and Long-Term Upside
Premium
Ratings
Cantargia: Solid Cash Runway and Expanding Nadunolimab Pipeline Support Buy Rating and Long-Term Upside
2M ago
Cantargia Highlights Pipeline Progress in 2025 Year-End Report
PremiumCompany Announcements
Cantargia Highlights Pipeline Progress in 2025 Year-End Report
2M ago
Cantargia Sets Date for 2025 Annual Results and Investor Presentation
PremiumCompany Announcements
Cantargia Sets Date for 2025 Annual Results and Investor Presentation
3M ago
Cantargia to Engage Investors at Leerink Global Healthcare Conference
PremiumCompany Announcements
Cantargia to Engage Investors at Leerink Global Healthcare Conference
3M ago
Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB
PremiumRatings
Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB
3M ago
Cantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer
PremiumCompany AnnouncementsCantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer
3M ago
Cantargia AB: Strategic Focus on PDAC and Autoimmune Indications Amid TRIFOUR Study Setback
Premium
Ratings
Cantargia AB: Strategic Focus on PDAC and Autoimmune Indications Amid TRIFOUR Study Setback
5M ago
Cantargia Reports TRIFOUR Study Results on Nadunolimab
Premium
Company Announcements
Cantargia Reports TRIFOUR Study Results on Nadunolimab
5M ago
Cantargia AB: Strategic Partnerships and Financial Stability Drive Buy Rating
PremiumRatings
Cantargia AB: Strategic Partnerships and Financial Stability Drive Buy Rating
5M ago
Cantargia AB Releases Interim Report Highlighting Strategic Progress
PremiumCompany Announcements
Cantargia AB Releases Interim Report Highlighting Strategic Progress
5M ago
Cantargia AB Announces Nomination Committee for 2026 AGM
PremiumCompany Announcements
Cantargia AB Announces Nomination Committee for 2026 AGM
6M ago
Cantargia AB to Release Interim Report and Host Investor Presentation
PremiumCompany Announcements
Cantargia AB to Release Interim Report and Host Investor Presentation
6M ago
Cantargia AB: Promising Oncology Pipeline and Strategic Partnership Drive Buy Rating
PremiumRatingsCantargia AB: Promising Oncology Pipeline and Strategic Partnership Drive Buy Rating
6M ago
Cantargia AB to Present at Key Investor Conferences
Premium
Company Announcements
Cantargia AB to Present at Key Investor Conferences
6M ago
Cantargia AB Appoints New Chief Medical Officer to Enhance Oncology Focus
Premium
Company Announcements
Cantargia AB Appoints New Chief Medical Officer to Enhance Oncology Focus
7M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >